Elzanor Txr 10/5/1000mg (14 Tablet / Pack)

An oral triple-action antidiabetic tablet combining empagliflozin, linagliptin, and extended-release metformin for type 2 diabetes management.

PKR 216.00

You save: PKR 0

Quantity:

SKU: ELZANOR_TXR_1051000MG_14_TABLET_PACK

Category: Tablets & Capsules

Elzanor Txr 10/5/1000mg (14 Tablet / Pack) is an oral triple-combination metabolic therapy containing empagliflozin, linagliptin, and extended-release metformin hydrochloride, formulated for advanced glycemic control. It functions via three complementary mechanisms: empagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2) in the kidneys to reduce renal glucose reabsorption and promote urinary glucose excretion; linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to elevate active incretin hormones, enhancing insulin secretion and suppressing glucagon output; and metformin reduces hepatic gluconeogenesis while improving peripheral insulin sensitivity.

Purpose

To improve glycemic control in adult patients presenting with type 2 diabetes mellitus when multi-component therapy is indicated.

Ingredients

Empagliflozin 10mg, Linagliptin 5mg, Metformin HCl (XR) 1000mg

Warnings

Swallow the tablets whole with a meal to optimize the extended-release profile and minimize gastrointestinal side effects; do not crush or chew. Discontinue therapy immediately and evaluate for ketoacidosis if symptoms like unexplained nausea, vomiting, abdominal pain, or dyspnea occur. Assess baseline renal function (eGFR) prior to initiation and monitor periodically, as the empagliflozin component depends on renal clearance. Educate patients on maintaining optimal perineal hygiene to mitigate the elevated risk of genital mycotic infections.

Side Effects

Gastrointestinal disturbances including mild nausea, abdominal discomfort, flatulence, temporary diarrhea, or an altered metallic taste. Increased risk of genitourinary tracts infections, including vulvovaginal candidiasis, balanitis, or mild urinary tract infections. Mild volume depletion symptoms such as orthostatic lightheadedness, increased urinary frequency, or dry mouth. Rare but severe metabolic complications including lactic acidosis (associated with metformin) or euglycemic diabetic ketoacidosis.